DAPPER.

Study name	An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER)
Methods	Multicentre, randomised, open‐labelled, parallel‐group, standard treatment‐controlled study
Participants	Type 2 Diabetes Mellitus patients with Chronic HF
Interventions	Interventions: Dapagliflozin 5‐10 mg/day; SGLT2i control: administration of anti‐diabetic drugs administered other than SGLT2i
Outcomes	Primary objective: Changes in the urinary albumin‐to‐creatinine ratio from the baseline after 2‐year treatment. Secondary objectives: (1) the safety of dapagliflozin and (2) the cardiovascular and renal efficacies of dapagliflozin.
Starting date	1 March 2017
Contact information	Fumiki Yoshihara, dapper‐study@ml.ncvc.go.jp, Hyogo College Of Medicine
Notes	UMIN000025102